Vontobel Holding
BCRX icon

Vontobel Holding’s BioCryst Pharmaceuticals BCRX Stock Holding History

Vontobel Holding’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-27,000
Closed -$257K – 1478
2026
Q1 		$257K Buy
+27,000
New +$210K ﹤0.01% 1040
2021
Q4 		– Sell
-43,800
Closed -$629K – 1064
2021
Q3 		$629K Sell
43,800
-7,000
-14% -$110K 0.01% 725
2021
Q2 		$803K Buy
50,800
+15,000
+42% +$204K 0.01% 646
2021
Q1 		$364K Hold
35,800
– – ﹤0.01% 743
2020
Q4 		$267K Buy
+35,800
New +$185K ﹤0.01% 828

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Vontobel Holding's BCRX Position: Q2 2026 in Review

Vontobel Holding sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2026, closing a stake of 27,000 shares — an estimated $257K sold.

Vontobel Holding first reported a position in BCRX in Q4 2020 and held it in 5 quarters. The position peaked at $803K in Q2 2021. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Vontobel Holding reported no remaining BioCryst Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Vontobel Holding sold 27,000 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $257K.
  • Vontobel Holding first reported a position in BioCryst Pharmaceuticals in Q4 2020 and held it in 5 quarters.
  • Vontobel Holding's BioCryst Pharmaceuticals position peaked at $803K in Q2 2021.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Vontobel Holding's 13F filing for Q2 2026, filed 3 Aug 2026.